leisure time -WSS

leisure time

author：Wikipedia 2025-09-06 01:55:19 - browse：654

gantenerumab Alzheimer's disease Roche — Sebastien Bozon/AFP via Getty Images

LONDON — Roche on Thursday said its recently acquired experimental obesity medication helped people lose a significant amount of weight in an early trial, sending its shares up in early trading.

The drug, a once-weekly injection known as CT-388, resulted in an average placebo-adjusted weight loss of 18.8% after 24 weeks, the company said. The study was a Phase 1 trial, though it was placebo-controlled.

The reaction to such an early result — Roche shares were up roughly 4% early Thursday — is a signal both of the stakes of the obesity medication race and the keen interest investors have in the field.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Boston hospital trains restaurant workers on naloxone for overdoses

leisure time

explore

WSS

IVG is promising — but it won’t replace IVF quite yet

Some top drug companies are starting to take action on climate

Supreme Court to hear if Covid misinformation is protected speech

Galapagos to make CAR

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

Fertility clinic egg and embryo storage is a disaster

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

knowledge

After affirmative action ruling, medical educators look to 'holistic review'

Free medical tuition alone isn't enough to close gaps in primary care

New air purifier tech could be key to improving indoor air quality

Setback for rare diseases as Taysha Gene Therapies pulls back

Anesthesiologist group: stop taking Ozempic before surgery

Nobel honors Karikó and Weissman's enduring partnership

Medical records are filled with copy

New oral drug delivery patch is modeled after octopus tentacles

New air purifier tech could be key to improving indoor air quality

Cherokee Nation medical school graduates its first class

Wikipedia

Galapagos to make CAR

The Karikó problem: Lessons for funding basic research

Some top drug companies are starting to take action on climate

CDC picks Alphabet's Verily for wasterwater surveillance contract

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

The stability of $0 premiums in Medicare Advantage

leisure time

explore

focus

knowledge